WO2006116423A3 - Compositions and methods for cancer immunotherapy - Google Patents

Compositions and methods for cancer immunotherapy Download PDF

Info

Publication number
WO2006116423A3
WO2006116423A3 PCT/US2006/015668 US2006015668W WO2006116423A3 WO 2006116423 A3 WO2006116423 A3 WO 2006116423A3 US 2006015668 W US2006015668 W US 2006015668W WO 2006116423 A3 WO2006116423 A3 WO 2006116423A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methods
compositions
cancer immunotherapy
compounds
Prior art date
Application number
PCT/US2006/015668
Other languages
French (fr)
Other versions
WO2006116423A2 (en
Inventor
Daniel P Rossignol
Sally T Ishizaka
Lynn D Hawkins
Scott Fields
Original Assignee
Eisai Co Ltd
Daniel P Rossignol
Sally T Ishizaka
Lynn D Hawkins
Scott Fields
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Daniel P Rossignol, Sally T Ishizaka, Lynn D Hawkins, Scott Fields filed Critical Eisai Co Ltd
Priority to CN2006800143808A priority Critical patent/CN101355928B/en
Priority to AU2006241206A priority patent/AU2006241206B2/en
Priority to KR1020077024654A priority patent/KR101205064B1/en
Priority to JP2008509049A priority patent/JP5185813B2/en
Priority to EP06751398.6A priority patent/EP1874342B1/en
Priority to CA2605749A priority patent/CA2605749C/en
Publication of WO2006116423A2 publication Critical patent/WO2006116423A2/en
Publication of WO2006116423A3 publication Critical patent/WO2006116423A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Abstract

The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.
PCT/US2006/015668 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy WO2006116423A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2006800143808A CN101355928B (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy
AU2006241206A AU2006241206B2 (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy
KR1020077024654A KR101205064B1 (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy
JP2008509049A JP5185813B2 (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy
EP06751398.6A EP1874342B1 (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy
CA2605749A CA2605749C (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67468005P 2005-04-26 2005-04-26
US60/674,680 2005-04-26

Publications (2)

Publication Number Publication Date
WO2006116423A2 WO2006116423A2 (en) 2006-11-02
WO2006116423A3 true WO2006116423A3 (en) 2008-10-09

Family

ID=37215428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015668 WO2006116423A2 (en) 2005-04-26 2006-04-26 Compositions and methods for cancer immunotherapy

Country Status (8)

Country Link
US (3) US7976852B2 (en)
EP (1) EP1874342B1 (en)
JP (2) JP5185813B2 (en)
KR (1) KR101205064B1 (en)
CN (2) CN101355928B (en)
AU (1) AU2006241206B2 (en)
CA (1) CA2605749C (en)
WO (1) WO2006116423A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
SI2347775T1 (en) 2005-12-13 2020-10-30 President And Fellows Of Harvard College Scaffolds for cell transplantation
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US9770535B2 (en) * 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US8501417B2 (en) * 2007-06-26 2013-08-06 Vanderbilt University Immunological compositions as cancer biomarkers and/or therapeutics
US20090170925A1 (en) 2007-10-29 2009-07-02 Eisai R&D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
WO2011063336A2 (en) * 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
AU2009215188B2 (en) 2008-02-13 2014-09-18 Dana-Farber Cancer Institute, Inc. Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) * 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
EP3266453A1 (en) 2008-07-03 2018-01-10 Mayo Foundation for Medical Education and Research Treating cancer
NZ595290A (en) * 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
EP2461828B1 (en) 2009-07-31 2017-06-21 President and Fellows of Harvard College Programming of cells for tolerogenic therapies
SG10201402917XA (en) * 2009-08-24 2014-08-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
CA2798074A1 (en) * 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
KR101477194B1 (en) * 2010-05-27 2014-12-29 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
JP2013538558A (en) 2010-07-19 2013-10-17 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Peptides based on the transmembrane domain of TOLL-like receptor (TLR) for treating TLR-mediated diseases
WO2013054329A1 (en) 2011-10-10 2013-04-18 Yeda Research And Development Co. Ltd. Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
JP5951615B2 (en) * 2010-10-01 2016-07-13 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Therapeutic use and combination therapy of TLR agonists
PT2624873T (en) 2010-10-06 2020-03-04 Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012105219A1 (en) * 2011-01-31 2012-08-09 オリンパス株式会社 Antibody therapy effect-enhancing drug
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
EP3417876B1 (en) 2011-04-28 2021-03-31 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
CN110078789A (en) * 2011-05-27 2019-08-02 Ambrx 公司 Composition of aplysiatoxin derivative, the method for being related to the aplysiatoxin derivative containing unnatural amino acid connection and application thereof
JP6062426B2 (en) 2011-06-03 2017-01-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ In situ antigen-producing cancer vaccine
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
JP6153526B2 (en) * 2011-09-06 2017-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Polypeptide vaccine
WO2013158673A1 (en) 2012-04-16 2013-10-24 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
NZ713941A (en) * 2012-06-07 2017-02-24 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates
CN103566377A (en) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
CN103768596B (en) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 For the combination product of oncotherapy, its purposes and correlation technique
CN105050619A (en) * 2012-12-03 2015-11-11 梅里马克制药公司 Combination therapy for treating HER2-positive cancers
JP2017503803A (en) 2014-01-10 2017-02-02 シャンハイ バーディー バイオテック インコーポレイテッド Compounds and compositions for treating EGFR expressing tumors
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
KR20210125603A (en) 2014-06-16 2021-10-18 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Treating myelomas
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN105233291A (en) * 2014-07-09 2016-01-13 博笛生物科技有限公司 Combined therapy composition and combined therapy method for treating cancers
CN105440135A (en) 2014-09-01 2016-03-30 博笛生物科技有限公司 Anti-PD-L1 conjugate for treating tumors
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
GB201501302D0 (en) * 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (en) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Immune cell capture device and its manufacture and use
US10842763B2 (en) * 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CA2994165A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
CN108290827B (en) 2015-07-31 2021-01-01 约翰霍普金斯大学 Prodrugs of glutamine analogs
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CN106943598A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research Methods of treating cancer with interferon
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CN107126563B (en) * 2016-02-26 2021-09-10 博生吉医药科技(苏州)有限公司 Composition containing low-dose antibody for blocking VEGF signal path and application thereof
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
KR102462041B1 (en) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Carrier for cancer treatment-PD-L1 binder composition
RU2019110071A (en) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч METHODS FOR TREATMENT OF MALIGNANT NOMINATIONS EXPRESSING PD-L1
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2021128415A (en) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч COMPOSITIONS WITH PACLITAXEL, ALBUMIN AND BINDING AGENT AND METHODS FOR THEIR APPLICATION AND PREPARATION
CN110913954A (en) * 2017-03-03 2020-03-24 黑曜石疗法公司 Compositions and methods for immunotherapy
CN108567977B (en) * 2017-03-13 2022-04-12 复旦大学 Immunopotentiator, immunotherapy pharmaceutical composition, preparation and application thereof
WO2018166298A1 (en) * 2017-03-13 2018-09-20 Fudan University Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
JP7080501B2 (en) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
WO2019102265A1 (en) 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
TW201946650A (en) 2018-03-12 2019-12-16 美商詹森藥物公司 Vaccines against intra-abdominal infections
JPWO2019240218A1 (en) 2018-06-14 2021-07-01 株式会社明治 Compositions for facilitating immune checkpoint inhibition therapy
WO2021050696A1 (en) * 2019-09-10 2021-03-18 The Research Foundation For The State University Of New York Compositions and methods for improving tumor penetration of tumor specific antibodies
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
JP2023500749A (en) 2020-01-16 2023-01-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド FimH variants, compositions thereof, and uses thereof
KR20230125842A (en) 2021-01-12 2023-08-29 얀센 파마슈티칼즈, 인코포레이티드 FimH mutants, compositions comprising them and uses thereof
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of e. coli o18 bioconjugates
WO2023168342A2 (en) * 2022-03-02 2023-09-07 Abreos Biosciences, Inc. Methods and compositions for measuring serum analyte levels from biological matrices

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707358A (en) 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
CN1074422C (en) 1987-11-18 2001-11-07 希龙股份有限公司 Nanbv diagnostics and vaccines
ATE130764T1 (en) 1988-10-17 1995-12-15 Cancer Res Campaign Tech ANTI-IDIOTYPE ANTIBODIES INDUCTION OF AN ANTITUMOR RESPONSE.
JPH06104789B2 (en) 1989-03-31 1994-12-21 日本ペイント株式会社 Metal pigment composition and aqueous coating composition containing the same
DE4123760C2 (en) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreactive areas on the HPV 16 proteins E1 and E2
AU2583892A (en) 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DK0732936T3 (en) * 1993-12-09 2000-09-04 Heinrich Exner Adjuvant to antigens, method of preparation and use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5840306A (en) 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
DE19511276C2 (en) * 1995-03-27 1999-02-18 Immuno Ag Adjuvant based on colloidal iron compounds
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
AU705549B2 (en) * 1995-06-07 1999-05-27 Promega Biosciences, Inc. Phosphonic acid-based cationic lipids
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
US6942862B2 (en) 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2330610A1 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
ATE219687T1 (en) * 1999-01-13 2002-07-15 Igeneon Krebs Immuntherapie USE OF ANTIBODIES FOR VACCINATION AGAINST CANCER
ES2347428T3 (en) * 1999-02-01 2010-10-29 EISAI R&D MANAGEMENT CO., LTD. IMMUNOLOGICAL COADYUVANT COMPOUNDS.
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
EP1183231B1 (en) 1999-05-28 2004-11-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
AU5345901A (en) * 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
KR100829674B1 (en) 2000-05-19 2008-05-16 코릭사 코포레이션 Prophylactic and Therapeutic Treatment of Infectious and Other Diseases with Mono- and Disaccharide-Based Compounds
JP4230765B2 (en) * 2000-07-31 2009-02-25 エーザイ株式会社 Immune adjuvant compounds, compositions and methods of use thereof
CA2421893A1 (en) * 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP2263465A1 (en) * 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalent conjugate vaccine for cancer
EP1496934A4 (en) * 2002-04-19 2006-08-02 Endocyte Inc Adjuvant enhanced immunotherapy
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1660636A4 (en) * 2003-08-26 2009-07-01 Univ Texas Anti-cancer vaccines
FR2863890B1 (en) * 2003-12-19 2006-03-24 Aventis Pasteur IMMUNOSTIMULATING COMPOSITION
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
JP6136343B2 (en) 2012-06-12 2017-05-31 株式会社リコー Information processing system, information processing method, program, and recording medium

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAWKINS L.D. ET AL.: "A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-L Receptor 4-Dependent Immunostimulatory Action, and Adjuvant Activity", J. PHARMACOL. EXP. THER., vol. 300, no. 2, February 2002 (2002-02-01), pages 655 - 661, XP002286603 *
HAWKINS L.D. ET AL.: "Inhibition of Endotoxin Response by Synthetic TLR4 Antagonists", CURR. TOP MED., vol. 4, no. 11, 2004, pages 1147 - 1171, XP002482811 *
ROSSIGNOL D.P. ET AL.: "TLR4 Antagonists for Endotoxemia and Beyond", CURR. OPIN. INVESTIG. DRUGS, vol. 6, no. 5, May 2005 (2005-05-01), pages 496 - 502, XP009104074 *

Also Published As

Publication number Publication date
CN103285392A (en) 2013-09-11
CA2605749C (en) 2015-06-30
WO2006116423A2 (en) 2006-11-02
EP1874342A4 (en) 2012-08-08
JP5185813B2 (en) 2013-04-17
US20070020232A1 (en) 2007-01-25
CN101355928B (en) 2013-05-22
JP5539460B2 (en) 2014-07-02
EP1874342B1 (en) 2018-06-06
US20140065100A1 (en) 2014-03-06
AU2006241206B2 (en) 2011-06-09
CA2605749A1 (en) 2006-11-02
AU2006241206A1 (en) 2006-11-02
EP1874342A2 (en) 2008-01-09
JP2012211196A (en) 2012-11-01
US8603482B2 (en) 2013-12-10
JP2008539249A (en) 2008-11-13
US7976852B2 (en) 2011-07-12
KR101205064B1 (en) 2012-11-27
US20110250171A1 (en) 2011-10-13
KR20070122510A (en) 2007-12-31
CN101355928A (en) 2009-01-28

Similar Documents

Publication Publication Date Title
WO2006116423A3 (en) Compositions and methods for cancer immunotherapy
WO2007056539A3 (en) Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
IL244803A0 (en) Humanized anti-beta7 antibodies and uses therefore
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
EP1937845A4 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2007127010A3 (en) Diarylthiohydantoin compounds
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009151717A3 (en) Bcr-complex-specific antibodies and methods of using same
WO2007007173A3 (en) Human anti-madcam antibodies
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2009026574A3 (en) Immunogenic compositions and uses thereof
MX2010006823A (en) Methods for the treatment of gout.
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680014380.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006241206

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2605749

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006751398

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008509049

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077024654

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU